Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Br J Pharmacol. 2011 Apr;162(8):1871-83. doi: 10.1111/j.1476-5381.2011.01200.x.
1,4-Naphthoquinones exhibit antiplatelet activity both in vivo and in vitro. In the present study, we investigated the antiplatelet effect of a novel naphthoquinone derivative NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone and its mechanism of action.
We measured platelet aggregation, Ca(2+) mobilization, thromboxane B2 formation and P-selectin expression and examined several enzymatic activities. Furthermore, we used the irradiated mesenteric venules in fluorescein sodium-treated mice to monitor the antithrombotic effect of NP-313 in vivo.
NP-313 concentration-dependently inhibited human platelet aggregation induced by collagen, arachidonic acid, thapsigargin, thrombin and A23187. NP-313 also inhibited P-selectin expression, thromboxane B(2) formation and Ca(2+) elevation in platelets stimulated by thrombin and collagen. NP-313 at 10 µM inhibited cyclooxygenase, thromboxane A(2) synthase, and protein kinase Cα, whereas it did not affect phospholipase A(2) or phospholipase C activity. In the presence of indomethacin and an adenosine 5-diphosphate scavenger, NP-313 concentration-dependently inhibited thrombin- and A23187-induced Ca(2+) increase through its inhibitory effects on Ca(2+) influx, rather than blocking Ca(2+) release from intracellular stores. NP-313 also inhibited thapsigargin-mediated Ca(2+) influx through store-operated calcium channel but had no effect on Ca(2+) influx through store-independent calcium channel evoked by the diacylglycerol analogue 1-oleoyl-2-acetyl-sn-glycerol. Nevertheless, it had little effect on cyclic AMP and cyclic GMP levels. Also, intravenously administered NP-313 dose-dependently inhibited the thrombus occlusion of the irradiated mesenteric vessels of fluorescein-pretreated mice.
Taken together, these results indicate that NP-313 exerts its antithrombotic activity through dual inhibition of thromboxane A(2) synthesis and Ca(2+) influx through SOCC.
1,4-萘醌在体内和体外均具有抗血小板活性。本研究旨在探讨新型萘醌衍生物 NP-313(2-乙酰氨基-3-氯-1,4-萘醌)的抗血小板作用及其作用机制。
我们测量了血小板聚集、Ca(2+)动员、血栓烷 B2 形成和 P-选择素表达,并检查了几种酶活性。此外,我们使用经荧光素钠处理的小鼠辐照肠系膜静脉来监测 NP-313 的体内抗血栓形成作用。
NP-313 浓度依赖性地抑制胶原蛋白、花生四烯酸、thapsigargin、凝血酶和 A23187 诱导的人血小板聚集。NP-313 还抑制了凝血酶和胶原蛋白刺激的血小板中 P-选择素表达、血栓烷 B2 形成和 [Ca(2+)]i 升高。NP-313 在 10 µM 时抑制环氧化酶、血栓烷 A2 合酶和蛋白激酶 Cα,而不影响磷脂酶 A2 或磷脂酶 C 活性。在吲哚美辛和腺苷 5-二磷酸清除剂存在的情况下,NP-313 浓度依赖性地抑制了凝血酶和 A23187 诱导的 [Ca(2+)]i 增加,这是通过其对 Ca(2+)内流的抑制作用,而不是通过阻断细胞内储存的 Ca(2+)释放。NP-313 还抑制 thapsigargin 介导的 Ca(2+)内流通过储存操作的钙通道,但对二酰基甘油类似物 1-油酰基-2-乙酰基-sn-甘油引起的非储存依赖的钙通道的 Ca(2+)内流没有影响。然而,它对 cAMP 和 cGMP 水平几乎没有影响。此外,静脉内给予 NP-313 剂量依赖性地抑制了经荧光素预处理的小鼠辐照肠系膜血管的血栓闭塞。
综上所述,这些结果表明,NP-313 通过双重抑制血栓烷 A2 合成和 SOCC 介导的 Ca(2+)内流来发挥其抗血栓形成活性。